Glucotrack completes first-in-human continuous blood glucose monitor implant study
Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose monitor (CBGM). The study included participants with both type 1 and type 2 diabetes and began enrolling patients in early December 2024.
At $1.15 a share, the offering is being done on a "best efforts" basis. Subject to usual circumstances, the business ...
Glucotrack has cleared the first human clinical study of its long-term continuous glucose monitoring implant, designed to ...
Hosted on MSN2d
Glucotrack hits trial success for direct blood measuring CGMThe company’s system is placed in the subclavian vein, a blood vessel that runs under the collar bone bringing deoxygenated ...
Glucotrack (GCTK) announced the pricing of a “best efforts” public offering of approximately 2.6M shares of common stock. The offering price of ...
The study met its primary endpoint with no procedure or device related serious adverse events reportedRUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK ...
RUTHERFORD, NJ - Glucotrack, Inc. (NASDAQ:GCTK), a developer of medical technologies for diabetes care, has announced the pricing of its public offering at $1.15 per share, aiming to raise ...
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable ...
Glucotrack, Inc. (Nasdaq: GCTK) disclosed a significant move within its capital structure. This Delaware corporation specializing in medical devices made public a press release involving a 1-for-20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback